Efficacy of Intralesional Methotrexate in the Treatment of Plantar Warts

Abdo, Hamed Mohamed; Elrewiny, Emad M.; Elkholy, Mohammed Shaban

doi:10.21608/ejhm.2019.43996

Cited by 4 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 However, previous studies evaluating intralesional injection of methotrexate in the treatment of plantar warts yielded non-satisfactory results. 9,10 In a randomized trial including 42 patients, aged 12-32 years, with common warts on two symmetrical limbs, each side was 22.6% for electrotherapy. Intralesional methotrexate was significantly less effective than electrocautery (p < 0.01).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intralesional full‐concentration (25 mg/ml) methotrexate in the treatment of plantar warts: A pilot study

Zoheir

Almohsen

Amer

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Plantar warts continue to represent a therapeutic challenge due to treatment resistance and high recurrence rates. Intralesional methotrexate, a cytotoxic chemotherapeutic agent with in-vitro anti-viral properties has been used for many dermatological indications. Two previous studies evaluated intralesional injection of diluted methotrexate (in 0.5, 1, and 2 mg/ml dilutions) in the treatment of warts and found it poorly effective.The concentrations used in these studies were much lower than those used for other indications. The current, open-label, prospective, pilot study aimed to evaluate the safety and efficacy of the intralesional injection of full concentration (25 mg/ml) methotrexate in the treatment of plantar warts. Twenty patients with plantar warts, 10 (50%) males, and 10 (50%) females, with mean ± SD age of 28.45 ± 8.66 years (range, 18-46 years) received biweekly sessions of intralesional methotrexate (25 mg/ml) until complete clearance or for a maximum of 6 sessions. Complete clearance of warts was achieved in 2 (10%), 6 (30%), and 7 (35%) patients after 4, 5, and 6 sessions, respectively. Another 8 (40%) patients showed partial improvement after 6 sessions. The response rate did not correlate significantly with the number of warts. Nine (45%) patients did not report any side effects. Pain and bruises were reported by 8 (40%) and 6 (30%) patients, respectively. These findings suggest that biweekly sessions of full (25 mg/ml) concentration of methotrexate are a safe and effective treatment for plantar warts. It may be considered an alternative line of treatment for resistant cases.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Intralesional methotrexate was significantly less effective than electrocautery (p < 0.01). 10 Abdo et al 9 2020 evaluated intralesional injections of diluted (2 mg/ml) methotrexate in the treatment of plantar warts. Sessions were repeated weekly for a maximum of 6 sessions.…”

Section: Discussionmentioning

confidence: 99%

Intralesional full‐concentration (25 mg/ml) methotrexate in the treatment of plantar warts: A pilot study

Zoheir

Almohsen

Amer

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…39 In a randomized controlled trial (n = 60), patients were split into IL-MTX (2 mg/ml) vs saline injections as placebo. 39 Injections were given every week for a maximum of six treatments. There was no statistically significant difference in response.…”

Section: Viral Wartsmentioning

confidence: 99%

“…Viral warts are benign lesions of the skin caused by human papillomavirus and can prove resistant to treatment. 39 MTX was found to have an anti-viral effect in cells infected with Zikavirus possibly through inhibition of dihydrofolate reductase. 40 It is plausible that MTX could act on viral warts in a similar manner (Table 4).…”

Section: Viral Wartsmentioning

confidence: 99%

See 1 more Smart Citation

Intralesional methotrexate in dermatology: Diverse indications and practical considerations

Searle

Ali

Al‐Niaimi

2020

Dermatologic Therapy

View full text Add to dashboard Cite

Intralesional methotrexate (IL‐MTX) is a long‐established treatment, which is arguably underutilized by dermatologists. We describe the underlying evidence base and practical considerations for its broad range of cutaneous indications, including in cutaneous oncology (keratoacanthomas, squamous cell carcinomas, lymphomas), inflammatory dermatology (nail psoriasis, plaque psoriasis, pyoderma gangrenosum, cutaneous Crohn's disease, amyloidosis), cutaneous infections (viral warts) and for treatment of filler complications. In certain circumstances, IL‐MTX can be more efficacious and less invasive than other treatments, with fewer adverse effects. Dermatologists should consider using IL‐MTX for a range of recalcitrant cutaneous conditions, particularly for those patients not amenable to surgery or systemic therapy.

show abstract

The impact of systemic psoriasis treatments on human papillomavirus activation and propagation

Korecka¹,

Wiśniewska-Szymańska²,

Mikiel³

2022

Aust J Dermatology

View full text Add to dashboard Cite

Psoriasis is one of the most prevalent diseases in the world and it affects up to 2% of the worldwide population. Its pathogenesis is complex and the lesions may be triggered by multiple factors. Human papillomavirus (HPV) is associated with anogenital cancers, cutaneous warts and is considered one of the most prevalent infections in the world. In this review, the available literature on the systemic treatment of patients with psoriasis and concomitant HPV infection was analysed.

show abstract

Efficacy of Intralesional Methotrexate in the Treatment of Plantar Warts

Cited by 4 publications

References 0 publications

Intralesional full‐concentration (25 mg/ml) methotrexate in the treatment of plantar warts: A pilot study

Intralesional full‐concentration (25 mg/ml) methotrexate in the treatment of plantar warts: A pilot study

Intralesional methotrexate in dermatology: Diverse indications and practical considerations

The impact of systemic psoriasis treatments on human papillomavirus activation and propagation

Contact Info

Product

Resources

About